On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Post-bariatric complications (dumping syndrome, malabsorption, vitamin deficiency, IDA) are coded as they occur with Z98.84 and the underlying obesity diagnosis if still clinically relevant
Tyagi K, Mandal S, Roy A
Read more Zepbound may cause temporary hair loss due to nutritional changes and stress
Why Ozempic Is Not Prescribed for Weight Loss at Klinic If you're curious about why Ozempic isn't prescribed for weight loss at Klinic, its because though it shares the active ingredient, semaglutide, with weight loss medications like Wegovy, their FDA approvals differ: Ozempic is for diabetes, and Wegovy is for chronic weight management
